Taxus Baccata

by | Mar 15, 2018 | Taxus Baccata

How Can We Help?
You are here:
< Back

Olmutinib (INN)[1] is an investigational anti-cancer drug. It acts by covalently bonding to a cysteine residue near the kinase domain of epidermal growth factor receptor (EGFR).[2]

In the US, it was given a breakthrough therapy designation in non-small cell lung cancer (NSCLC) in December 2015, and In South Korea, the drug was approved in May 2016 for the second-line treatment of NSCLC with the T790M mutation of EGFR.[2] Resistance to olmutinib has been reported; a person's cancer started progressing after they developed a C797S mutation in EGFR.[2][3]

Olmutinib was discovered by Hanmi Pharmaceutical and licensed to Boehringer Ingelheim in 2015 in an agreement with a $50 million up front payment and up $680 million in milestones.[4] In November 2015 Hanmi granted an exclusive license to sell olmutinib in China to the Chinese company ZAI Labs.[5]

On September 30, 2016, Korean regulatory authorities issued a safety alert about olmutinib in which it described two cases of toxic epidermal necrolysis, one of which was fatal, and a case of Stevens–Johnson syndrome; Boeheringer announced the termination its deal with Hanmi the same day, citing that the decision came after a review of "all available clinical data" on the drug, and also referring to competing drugs.[6]

References

  1. ^ "Olmutinib". AdisInsight. Springer Nature Switzerland AG. Retrieved 28 February 2017.
  2. ^ a b c Liao BC, Lin CC, Lee JH, Yang JC (December 2016). "Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors". Journal of Biomedical Science. 23 (1): 86. doi:10.1186/s12929-016-0305-9. PMC 5135794. PMID 27912760.
  3. ^ Passaro A, Guerini-Rocco E, Pochesci A, Vacirca D, Spitaleri G, Catania CM, et al. (March 2017). "Targeting EGFR T790M mutation in NSCLC: From biology to evaluation and treatment". Pharmacological Research. 117: 406–415. doi:10.1016/j.phrs.2017.01.003. PMID 28089942. S2CID 45855336.
  4. ^ Garde D (July 29, 2015). "Boehringer bets up to $730M on a new lung cancer drug". FierceBiotech.
  5. ^ Keenan J (April 14, 2016). "South Korea's Hanmi to spend $200M in China expansion". FiercePharma.
  6. ^ Carroll J (October 1, 2016). "Following lethal tox report, Boehringer scraps plans for high-speed development, kills $730M Hanmi deal". Endpoints.


Categories
Table of Contents